Immunotherapy in Melanoma: Recent Advancements and Future Directions.

Cancers (Basel) · 2023 · PMC10452647 · PMID 37627204

Europe PMC DOI

hedged sentence

0.0593

closest p · 1.2× alpha

0.0593

boldest claim

The sentences

did not reach statistical significancep = 0.0593so close (0.05 < p ≤ 0.1)

Data demonstrate improved progression-free survival (median PFS: 10.1 months versus 4.6 months) as well as overall response rates (43.1% versus 32.6%) for the combination and, with 19.3 months of follow-up, a numerical improvement in OS, although this did not reach statistical significance (HR 0.80, confidence interval 0.064–1.01, p = 0.0593).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.